Senior Director, Pipeline Market Access Strategy - Immunology
AbbVie
Summary
The Senior Director, Pipeline Market Access Strategy (PMAX) is a newly created role responsible for leading and inspiring the end-to-end global market access strategy for pipeline assets within their assigned Business Unit. This role bridges early asset development and future commercialization readiness, ensuring that pricing and access considerations are embedded from the earliest stages of the drug development lifecycle and through Phase 3 design and identification of evidence needs.
Job description
Key Responsibilities
Pipeline Access Strategy & Portfolio Leadership
- Owns the end-to-end pipeline Integrated access strategy for all pre-launch and development-stage assets within the assigned Business Unit
- Serves as the primary voice of pipeline market access strategies at Business Unit governance forums
- Serves as the voice of access into pipeline Business Development opportunities
- Leads prioritization exercises across the pipeline portfolio
- Creates and optimizes launch strategies inclusive of considerations for IRA, MFN, and other market forces
- Defines and delivers the Access Roadmap
Early Development Integration
- Partners with R&D and Regulatory teams to embed access-relevant endpoints, comparators, and trial design elements into clinical development programs
- Defines and champions Target Product Profiles (TPPs) from a market access perspective
- Generates and maintains global payer and HTA evidence requirements across major markets
US & International Strategy Alignment
- Provides strategic leadership and direction to the US Pipeline Strategy Lead and International Pipeline Strategy Lead
- Aligns US payer strategy, formulary positioning, and value communication frameworks with international HTA, pricing, and reimbursement approaches
- Anticipates cross-market reference pricing dynamics, parallel trade risks, and HTA precedent effects
- Partners closely with US and International Pipeline Strategy Leads to develop and execute a structured pipeline-to-launch transition framework
- Collaborates with US and international commercial, medical, and market access teams
- Leads cross-functional launch readiness reviews
- Ensures that affiliate and in-country market access teams are equipped with globally aligned value messages
Cross-Functional Leadership & Partnership
- Provides strategic direction and partnership to cross-functional groups including HEOR, R&D, Regulatory, Global Commercial Development, Global Marketing, Government Affairs, and Business Development
- Leads the development of Integrated Evidence Plans (IEPs) in close collaboration with HEOR
- Partners with Government Affairs to anticipate and shape the evolving policy and reimbursement landscape
- Collaborates with Global Commercial Development and Global Marketing
Business Development & Asset Evaluation
- Works closely with Business Development to inform the market access potential of in-licensing, partnership, and acquisition opportunities
- Establishes and communicates access-based licensing priorities
- Serves as the access subject matter expert in due diligence processes
Governance, Stakeholder Engagement & People Leadership
- Represents pipeline market access priorities at senior leadership governance forums
- Builds, develops, and retains a high-performing pipeline access team
- Fosters a culture of innovation, rigor, and affiliate-centricity within the pipeline access team
Requirements
- Advanced degree (MBA, MPH, PhD, PharmD, or equivalent) in business, health economics, public policy, life sciences, or a related field is required
- Bachelor's degree in a scientific, business, or public health discipline is required as a minimum baseline
- Formal training or demonstrated expertise in health technology assessment (HTA), health economics, outcomes research, or pharmaceutical development is strongly preferred
- A minimum of 12–15 years of progressive, senior-level experience in market access, pricing, reimbursement, HEOR, or a closely related pharmaceutical/biopharmaceutical function
- Substantial portion of experience focused on pipeline and pre-launch strategy
- Demonstrated expertise in global market access, including deep working knowledge of HTA processes, payer evidence requirements, pricing and reimbursement frameworks, and access decision-making dynamics across major international markets (US, EU5, Japan, and additional key markets)
- Proven experience shaping clinical development strategy from a market access and outcomes evidence perspective
- Direct experience contributing to clinical trial design, endpoint selection, and Integrated Evidence Plan development in collaboration with R&D teams
- Strong track record of leading and developing high-performing teams in a matrixed, multinational environment
- Demonstrated ability to manage direct reports and influence cross-functional partners without direct authority
- Experience supporting Business Development activities including asset due diligence, licensing evaluations, and access-based valuation assessments is highly preferred
- Comfortable operating at the senior leadership level with demonstrated ability to communicate complex access strategy to executive audiences
- Experience across multiple therapeutic areas (e.g., Oncology, Immunology, Neuroscience) is an asset, though deep expertise in at least one is required
Benefits
- Paid time off
- Medical, Dental & Vision
- 401(k)
- Long-term incentive programs
Company overview
AbbVie is a global biopharmaceutical company that discovers, develops, and markets advanced therapies for some of the world's most complex and serious diseases. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has established itself as a leader in immunology, oncology, neuroscience, eye care, and virology. The company's flagship product, Humira (adalimumab), was one of the world's top-selling drugs for treating autoimmune conditions like rheumatoid arthritis and Crohn's disease. AbbVie maintains a robust pipeline of innovative medicines and has expanded its portfolio through strategic acquisitions, including Allergan in 2020. With research facilities across the United States and globally, AbbVie focuses on advancing science to improve patient outcomes while maintaining strong commercial operations worldwide. The company operates with a patient-centric approach and invests significantly in research and development to address unmet medical needs across multiple therapeutic areas.